tetrahydrozoline, ophthalmic (Visine Advanced Relief, Visine Maximum Redness Relief, Visine Original, Rohto Arctic)

Dosing and uses of Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic)

• Adult
• Pediatric

 

Adult dosage forms and strengths

ophthalmic drops

• 0.05%

 

Conjunctival Congestion

Temporary relief of ocular redness caused by irritation & relief of burning or irritation caused by dry eyes

1-2 gtt to affected eye q6-12hr

Not to exceed 72 hours of use

 

Administration

Remove contact lenses before use

Do not use if this solution changes color or becomes cloudy

Do not touch tip of container to any surface to avoid contamination

Replace cap after each use

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic) adverse (side) effects

Frequency not defined

Irritation/burning

Blurred vision

Headache

Tremor

Hypertension

Tachycardia

Palpitation

 

Warnings

Contraindications

Hypersensitivity

 

Cautions

Narrow angle glaucoma

May cause temporary mydriasis

Use caution in hypertension, coronary artery disease, diabetes, and hyperthyroidism

Discontinue and seek medical advice if the following occur: eye pain, changes in vision, redness or irritation of the eye lasts >72 hr

 

Pregnancy and lactation

Pregnancy category: C

Lactation: not known if distributed in milk

Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Visine Advanced Relief, Visine Maximum Redness Relief (tetrahydrozoline ophthalmic)

Mechanism of action

May stimulate alpha-adrenergic receptors in the arterioles of the conjunctiva; produces vasoconstriction

May produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants

 

Pharmacokinetics

Duration: 2-3hr (vasoconstriction)